Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound ...

Eli Lilly on Thursday posted better-than-expected quarterly results, although sales of its popular weight-loss drug, Zepbound ...

The obesity drug price wars are finally starting. After being publicly lambasted for the high cost of their weight-loss shots ...

The lower rating came from HSBC, which cited too much optimism around its new weight-loss pill, and the strength of Novo ...

Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro surged in the first quarter.

Eli Lilly's (LLY) stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said the drugs Wegovy and Saxenda from rival drugmaker ...

Eli Lilly announced clinical trial results this week for a daily pill to treat obesity and diabetes. Its name is absolutely ...

Sales of diabetes drug Mounjaro were $3.84 billion, exceeding analysts' estimates of $3.80 billion. Mounjaro is also the brand name used for weight loss outside the U.S. Lilly cut its full-year ...

Pharmaceutical company Eli Lilly announced promising clinical trial results this week for a daily pill to treat obesity and diabetes. Besides the good news of minimal side effects and impressive ...

Novo Nordisk has launched a direct-to-consumer (DTC) option for uninsured or under-insured people wanting to access its GLP-1 agonist weight-loss drug Wegovy ... rival Eli Lilly adopted a similar ...